

The Effects of Influenza Vaccination on Immune Function in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

E.W. Brenu^{1,2*}, M. van Driel^{1,4}, D.R. Staines^{1,5}, S. Kreijkamp-Kaspers^{1,2}, S. L. Hardcastle^{1,2}, S.M. Marshall-Gradisnik^{1,2,3}

¹Faculty of Health Science and Medicine, Population Health and Neuroimmunology Unit, Bond University, Robina, QLD, Australia; ²Faculty of Health Science and Medicine, Bond University, Robina, QLD, Australia; ³School of Medical Science, Griffith Health Institute, Griffith University, Gold Coast Campus, Gold Coast, QLD, Australia; ⁴Discipline of General Practice, School of Medicine, University of Queensland, Brisbane, Australia; ⁵Queensland Health, Gold Coast Public Health Unit, Robina, Gold Coast, QLD, Australia.

Email: *e.brenu@griffith.edu.au

Received ***** 2012

ABSTRACT

Immune dysfunction is a hallmark of Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME). The purpose of this pilot study was to identify the effects of influenza vaccination on immune function in patients with CFS/ME. We included 7 patients meeting the Centre for Disease Control and Prevention criteria (CDC 1994) for ME/CFS and 8 control subjects. Bloods were collected from all participants prior to vaccination with Inluvac a trivalent inactivated influenza vaccine (TIV), 14 and 28 days following vaccination. The immune parameters examined include Natural Killer (NK) phenotypes, NK cytotoxic activity, FOXP3 and Th1/Th2/Th17 related cytokines. Flow cytometric protocols were employed. There was no significant difference in NK phenotypes and Tregs numbers between CFS/ME patients and healthy controls. However, NK activity was significantly decreased at baseline and at 28 days while at 14 days it was significantly increased in the CFS/ME patients compared to the healthy controls. Th1 pro-inflammatory cytokines were much more increased in the CFS/ME patients at 28 days compared to the non-fatigued controls. Only one Th2 cytokine, IL-4, was increased in the CFS/ME participants. FOXP3 expressing Tregs were significantly increased only at day 28 post vaccination in the CFS/ME patients compared to the healthy controls. Self-rated wellbeing was lower for patients at day 28 while at baseline and day 14 no differences were observed. In this pilot study immunization with influenza vaccine is accompanied by a degree of immune dysregulation in CFS/ME patients compared with controls. While vaccination may protect CFS/ME patients against influenza, it has the ability to increase cytotoxic activity and pro-inflammatory reactions post vaccination. The role of Tregs in promoting a toxic effect at 28 days post-vaccination in our patient group cannot be ruled out. The benefits of influenza vaccine still likely outweigh the risks CFS/ME patients experience following vaccination.

Keywords: Chronic Fatigue Syndrome; Influenza; Vaccination; Natural Killer Cells; Cytokines

1. Introduction

The influenza virus is genetically variable thus new vaccines are developed annually to ensure effective protection against the new strains of the virus. Variation in the virus mainly occurs in the main viral glycoproteins, haemagglutinin (H) and neuraminidase (N) [1]. The immune system is important in eliminating and clearing viral infections. Usually, during an influenza infection, recognition of an infected cell occurs via the retinoic acid inducible gene I (RIG-I) while influenza genomic RNA is detected by the Toll-like receptor 7 (TLR-7) [2-4].

This stimulates the generation and production of soluble proteins belonging to the type I interferon (IFNs) family and which in turn suppress viral reproduction [5]. Both the innate and adaptive immune systems are required to combat viral infections. In the innate immune system, macrophages secrete IL-1 β and IL-18 [6] while the adaptive immune system cells such as CD4+ T and CD8+ T cells generate influenza specific memory cells. These cells are equipped to recognize conserved sequences within the virus that serve as a protective mechanism for the virus by making them undetectable for the vaccine [7,8].

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a disease with unknown aetiology cha-

*Corresponding author.

racterized by severe fatigue and flu-like symptoms [9,10]. CFS/ME affects a substantial number of people worldwide and has been associated with a number of viruses [11-15]. Although the exact cause of CFS/ME is unknown, serological studies have shown high rates of viral titres in CFS/ME patients [15-18]. This may indicate an inability to effectively clear infections as immune function has been shown to be decreased in CFS/ME patients when compared to non-CFS/ME individuals [19-22]. A number of factors such as mental, physical, psychological stresses and viral infections may exacerbate the symptoms of CFS/ME [23].

Administration of TIV in general to CFS/ME patients is a controversial issue [1,24-29]. This is mainly related to the view that vaccines may affect the immune system in CFS/ME patients resulting in a worsening of symptoms and consequently physical health. Incidentally, a survey of CFS/ME patients revealed that 31% of patients who had not received the influenza vaccination were of the view that immunization was hazardous to their health. However, among patients who had been vaccinated and developed complications 28% were optimistic and 26% agreed that vaccines were not detrimental to their health [29]. The degree of support for the influenza vaccine was higher among CFS/ME patients who had experienced positive outcomes from previous vaccinations, in this group, 45% rated vaccinations as favourable while 55% agreed it was advantageous [29]. A recent study investigated the effect of influenza vaccination on immune response noted that in some cases, administration of whole virus influenza vaccine was observed to raise antibody titres with no significant side effects in the CFS/ME group in comparison to the non-CFS/ME group [27]. Additionally, there was no significant difference in the symptoms of CFS/ME patients with or without the influenza vaccine 6 weeks after vaccination [27]. The results of this first study suggest that there is no demonstrable impact on the ability to generate antibodies, however the effect on cellular immunity, which is known to be affected in CFS/ME has not been studied before. Whole virus influenza vaccines are also inactivated however due to adverse events with whole virus influenza vaccines, only split virus influenza vaccines have been available in the US since 2001.

The purpose of this study is to explore the effects of influenza vaccination on immune function in CFS/ME patients, by examining and comparing NK activity, NK phenotypes, cytokine secretion pre, 14 and 28 days post vaccination.

2. Materials and Methods

2.1. Participants

A total of 15 participants were selected from a database

of patients living in the South East Queensland region of Australia [30]. Seven patients were classified as having CFS/ME using the Centre of Disease Prevention and Control (CDC) 1994 case definition [1]. The non-CFS/ME controls comprised 8 participants from the same region. Written consent was obtained from all participants prior to blood sampling. A volume of 40mL of non-fasting morning blood samples were collected from the antecubital vein into lithium heparin and EDTA tubes. Full blood count measurements were obtained prior to immunological assessments.

2.2. Vaccine Intervention

Prior to vaccination contraindications for vaccination were checked as per the Australian immunisation handbook [32]. In the absence of contraindications the vaccine was administered by intramuscular injection in the deltoid muscle by a doctor. The patient was observed for at least 15 minutes post vaccination to monitor any immediate adverse effects. The type of influenza vaccine used was Influxac (Solvay Pharmaceuticals) an inactivated influenza vaccine. Each 0.5 mL pre-filled syringe contains 15 µg haemagglutinin of each of the three recommended strains produced for the 2011 flu season ((2011) A/California/ 7/2009 (H1N1) - like strain, A/Perth/ 16/2009 (H3N2) - like strain and B/, Brisbane/60/2008 - like strain). The vaccine batch number was documented on the day of administration. At follow up patients were asked to report any adverse effects following vaccination. At every blood collection participants self-rated their general wellbeing, cold and flu symptoms and mood on a visual analogue scale (VAS), with the best imaginable or no symptoms rated as 0 and the worst imaginable as 10.

2.3. NK Cytotoxic Activity

A flow cytometric based cytotoxic protocol was used to measure NK cytotoxic activity [19,33,30]. This involved isolating peripheral blood mononuclear cells (PBMCs) from whole blood samples using density gradient centrifugation. Subsequently cells were labeled with 0.4% PKH-26 (Sigma, St Louis, MO). PBMCs were then incubated with K562 cells, for 4 hours at 37°C in 95% air, 5% CO₂ using a ratio of 25 (NK cells):1 (K562). Apoptosis of K562 cells were analyzed [19,30] via FACS-Calibur flow cytometry (BD Bioscience, San Jose, CA), after labeling cells with Annexin V-FITC and 7-AAD reagent (BD Pharmingen, San Diego, CA).

2.4. NK Phenotypes Quantitation

NK cell subsets distribution, *i.e.* CD56brightCD16- NK cells and CD56dimCD16+ NK cells was determined as previously described [19,30]. Preferential isolation of

NK cells was performed using a negative selection system, RosetteSep Human Natural Killer Cell Enrichment Cocktail (StemCell Technologies, Vancouver, BC) from whole blood. NK cells were labeled with monoclonal antibodies for CD56 (FITC) and CD16 (PE) (BD Pharmingen, San Jose, CA).

2.5. Cytokine Secretion Following Mitogenic Stimulation

Cytokines were measured following mitogenic stimulation of cultured PBMCs. In brief PBMCs were isolated from whole blood using ficoll-hypaque density gradient centrifugation. PBMCs were placed in cell culture media with or without 1 µg of phytohemagglutinin for 72 hours at a concentration of 1x10⁶ cells/mL in RPMI culture media at 37°C in 95% air with 5% CO₂. Cell supernatants were collected immediately and stored at -800 C for later assessment. Th1, Th2 and Th17 cytokine profiles were determined using the cytometric bead array kit (BD Pharmingen, San Jose, CA) [30,34]. The concentrations of the following cytokines IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, interferon (INF)-γ and IL-17A were measured.

2.6. Examination of Regulatory T Cells in CFS/ME Patients.

Assessment of Tregs was performed as previously described [30]. In short PBMCs isolated from 10ml of whole blood were washed and stained with monoclonal antibodies FITC-CD4 and APC-CD25 (BD Pharmingen, San Diego, CA). Cells were then permeabilised and fixed with buffers containing diethylene glycol and formaldehyde. Subsequently, cells were stained with PE-FOXP3 and evaluated on the flow cytometer. FOXP3 was determined on CD4⁺ CD25⁺ T cells.

2.7. Statistical Analysis

Statistical analysis was performed using SPSS software version 18.0. All data are reported as means plus/minus standard error of the mean (±SEM). The analysis of variance test (ANOVA) and repeated measures was used to compare continuous data. As the different variables were examined at three different time points, time was considered as the within-subjects factor while group was the between-subject factor. Changes in data between time points were further assessed using Bonferroni post-hoc analysis. To determine within subject stability Pearson and Spearman's rank correlations were determined between the three time points. Significance was set at P-values less than or equal to 0.05.

Approval for this study was obtained from the Bond University Human Research Ethics Committee.

3. Results

3.1. Abbreviations and Acronyms

The study population consisted of 7 CFS/ME patients, on average 48 years old and 8 controls, average age 38 years old and all female. All patients fulfilled the CDC criteria for CFS. At baseline there were no statistically significant differences between the two groups but at day 14 and more clearly at day 28 post vaccination the CFS/ME patients record a significantly lower general wellbeing compared to the controls (Figure 1).

3.2. Assessment of NK Cytotoxic Activity

NK cytotoxic activity was significantly decreased ($p < 0.05$) in CFS/ME patients compared to the control group prior to vaccination and at 28 days following vaccination. However, there was no significant decrease in the two groups at 14 days post vaccination (Figure 2).

3.3. Distribution of NK Cells

NK phenotypes were classified as CD56dimCD16+ and CD56brightCD16- NK cells. CD56dimCD16+ and CD56brightCD16- NK cells numbers were not significantly different at any of the time points in the CFS/ME patients compared to non-fatigued controls.

3.4. Mistakes

Cytokine secretion following mitogenic stimulation did not differ before and 14 days after vaccination in the CFS/ME and control group. At 28 days post vaccination significant increases in IL-4, IL-17A, IFN-γ and TNF-α were observed in the CFS/ME patient compared to the




Figure 1. Self rated wellbeing in the CFS/ME and non-fatigued controls. The graph represents wellbeing of the participants (CFS/ME and non-fatigued controls) throughout the study that is at baseline, day 14 and day 28. The ■ represent control data while ● depicts the CFS/ME data. Data are presented as means ± SEM. *Represents a statistical significant result in relation to controls, P < 0.05 vs. non-fatigued control.




Figure 2. NK cytotoxic activity pre and post vaccination. NK cytotoxic activity is presented as the % of K562 cells lysed by NK cells pre (baseline) and post vaccination (day 14 and day 28) in the non-fatigue control group (white bars) while and the CFS/ME group (black bars). *Represents a statistical significant result in relation to controls. Data are presented as means \pm SEM.

controls (Figures 3(a), (b), (c) and (d)). There was no significant difference in FOXP3 pre and 14 days post vaccination. However, an increase in FOXP3 was observed 28 days post vaccination in the CFS/ME group compared to the controls (Figure 4).

4. Discussion

Our small pilot study suggests that vaccination with seasonal inluvac vaccine, Influenza vaccine, may affect cellular immune function in CFS/ME patients, such as increase of NK function and differential changes in the expression of release of certain proteins by lymphocytes. However, the phenotypes of immune cells such as NK phenotypes may not necessarily be affected by influenza vaccines as these cells remained unchanged post vaccination. An increase in T cell related proteins occurred post vaccination. Overall wellbeing of the patients was significantly lower on the last day of the study. The idea behind the seasonal administration of the influenza vaccine relates to its ability to protect against the effects of




Figure 3. Levels of different cytokines pre and post vaccination. The graph (a) represents the secretion of IL-4; (b) TNF- α ; (c) IFN- γ and (d) IL-17A pre (baseline) and post vaccination (day 14 and day 28). The white bars depict data from the non-fatigued controls and the black bars are representative of the CFS/ME patients. Data are presented as means \pm SEM. *Represents a statistical significant result in relation to controls, $P < 0.05$.




Figure 4. Intracellular FOXP3 expression pre and post vaccination. The graph represents the FOXP3 production from intracellular staining of Treg cells pre (baseline) and post (day 14 and day 28) vaccination. The white bars depict data from the non-fatigued controls and the black bars are representative of the CFS/ME patients. Data are presented as means \pm SEM. *Represents a statistical significant result in relation to controls, $P < 0.05$.

different strains of the influenza virus. Previous studies have confirmed the protective effects of certain vaccines on the immune system in CFS/ME patients [1,26,28]. To our knowledge this is the first study to report the impact of influenza vaccination on the cellular immune system in CFS/ME patients.

Immune cell function, in particular, NK cytotoxic activity was decreased prior to vaccination and 28 days post vaccination and increased at day 14 in the CFS/ME group compared to the non-fatigued controls. This suggests that TIV affected responses in the immune system 14 days after vaccination, however, this immune response returned to its initial status at 28 days following vaccination as NK cytotoxic activity was decreased at both baseline and day 28. The cause of the increase in NK activity in the CFS/ME patients following vaccination is not explicitly known, however, administration of TIV and LAIV influenza vaccines have the potential to induce cytotoxic activity in NK cells. Importantly, these vaccines are known to generate memory cytotoxic cells in cytotoxic CD8⁺ T cells that are important for preventing influenza [35,36].

The mechanism of cytotoxic activity involves the activation of granule dependent pathways which facilitate the release of cytolytic proteins, perforin and granzymes, into the cytoplasm of the viral or tumor cell. Influenza virus decreases the expression of these molecules in particular perforin [37]. Incidentally, administration of TIV increases the expression of perforin in CD8⁺ T cells and this likely occurs in NK cells, thereby enhancing cyto-

toxic activity in some cells [38]. In adults, reduced levels of granzyme B increase the threat of influenza. However, high levels of granzyme B and NK activity have been observed to be relatively higher in older compared to younger individuals following influenza vaccination [39, 40]. This presupposes that the influenza vaccine may enhance cytotoxic activity by prolonging the cytotoxic process and increasing the presence of lytic proteins in cytotoxic cells. The type of influenza vaccine used may have an impact on the activity of NK cells. For example NK cell activity is prolonged in the presence of TIV [41]. Hence, this may be a contributory factor to the elevated cytotoxic activity following influenza vaccination with the TIV used in our patients. These findings would tend to support the rationale that influenza vaccines are protective rather than harmful in most individuals. Additionally, the significant decrease in cytotoxic activity may be correlated with the low levels of wellbeing 28 days after vaccination. This is consistent with the literature associating reduced well-being with low immune function in particular decreases in NK cell cytotoxic activity [42]. However, the rise in inflammatory cytokines at this time point together with potentially pathogenic regulatory T cell activity may suggest enhanced toxicity contributing to a lowered sense of well-being.

The majority of the cytokines that were significantly increased in the CFS/ME patients were Th1 cytokines including IFN- γ and TNF- α , IL-17 was also increased. IL-4 was the only Th2 cytokine that was increased in the CFS/ME patients compared to the non-fatigued controls. Hence, it can be deduced that influenza vaccines may increase the production of both pro- and anti-inflammatory cytokines in the CFS/ME patients. This observation is consistent with the observation that CFS/ME patients have some background dysregulation of their immune system and correlates with the clinically reported worsening of symptoms. However Influenza vaccines can cause headaches, arthralgia, fever, nausea and malaise [43], which coincidentally are symptoms of CFS/ME.

The effect of the influenza vaccine on the immune system in terms of cytokine response is not immediate and seems to occur at a later stage. In the adaptive immune system vaccines such as the TIV effectively prompt Th1 related immune response which is characterized by the presence of IL-2 [44]. Similarly, an increase in IL-17 was observed after vaccination of mice with TIV. Although these studies were done in mice they may provide a snapshot of the actual effects of inactivated influenza vaccines on the human immune system. Cytokine effects were only observed 28 days post vaccination, prior to this no significant changes in cytokines were observed. A predominant Th1 immune response suggests that an increase or exacerbation in pro-inflam-

matory activity is possibly occurring in the CFS/ME patients. However, in a previous study we reported that cytokines tend to fluctuate in CFS/ME patients and this may persist following vaccination, although, the samples sizes for these patients were much smaller than those used in the previous studies and too small to draw further conclusions. Similarly, in vitro examination of different types of influenza vaccines shows the ability to stimulate a Th1 immune type response in PBMCs, which again was more prevalent in the older compared to the younger participants [45,46]. This is suggestive of an improvement in immune response as a consequence of administration of vaccines.

This pilot study demonstrates the potential effects of TIV on immune function in CFS/ME patients compared to non-fatigued individuals. The cause of the heightened cytotoxic activity is not clear, however, this increase in cytotoxic function is subsequently followed by an increase in pro-inflammatory cytokines. Whether this substantial increase in cytokines is related to the influenza vaccine is not entirely known as cytokines have the tendency to oscillate; however, no oscillations were observed pre vaccination and at day 14. Interestingly altered Treg function at 28 days may also influence lowered well-being in this patient group, however more investigations are required to see if the Treg subset may be pathogenic. The influenza vaccine may play a role in modifying the pattern of immune expression observed in our CFS/ME patients.

Our study has limitations. A relatively small sample size of patients and controls was used and this may have biased the changes observed in the parameters measured. Additionally, immune measurements were not taken within the first few days post vaccination. These measurements may be important in determining the rate of change in cytotoxic activity and cytokines immediately after administering the vaccine. In addition, only one type of vaccine, *i.e.* the TIV, was investigated. Perhaps future studies on the effects of other vaccines on the immune system may be important in disseminating the type of vaccines to recommend to CFS/ME individuals.

5. Conclusion

In conclusion, the challenge of determining the most effective intervention against influenza in individuals with complex disorders such as CFS/ME remains to be determined. Influenza vaccines such as TIV may be important in increasing immunity against pathogens by increasing cytotoxic mechanisms and pro-inflammatory cytokines. However, as the effectiveness of influenza vaccines is not 100% in all individuals, it is possible that in some cases vaccination against influenza may be protective as it has the ability to increase cytotoxic activity and pro-

inflammatory reactions post vaccination while adverse effects may ensue in others. Therefore these vaccines should be administered with caution in patients with complex disorders where immune function is severely compromised. The advantage of influenza vaccine may likely offset the risks associated with CFS/ME.

REFERENCES

- [1] P. Magnus, O. Brubakk, H. Nyland, B. H. Wold, H. K. Gjessing, I. Brandt, T. Eidem, H. Nokleby, and G. Stene-Larsen, "Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome," *Vaccine*, vol. 27, pp. 23-7, 2009. [doi:10.1016/j.vaccine.2008.10.043](https://doi.org/10.1016/j.vaccine.2008.10.043)
- [2] S. S. Diebold, T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa, "Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA," *Science*, vol. 303, pp. 1529-31, Mar 5 2004. [doi:10.1126/science.1136080](https://doi.org/10.1126/science.1136080)
- [3] H. Kato, S. Sato, M. Yoneyama, M. Yamamoto, S. Uematsu, K. Matsui, T. Tsujimura, K. Takeda, T. Fujita, O. Takeuchi, and S. Akira, "Cell type-specific involvement of RIG-I in antiviral response," *Immunity*, vol. 23, pp. [doi:10.1016/j.immuni.2005.04.010](https://doi.org/10.1016/j.immuni.2005.04.010)
- [4] J. M. Lund, L. Alexopoulou, A. Sato, M. Karow, N. C. Adams, N. W. Gale, A. Iwasaki, and R. A. Flavell, "Recognition of single-stranded RNA viruses by Toll-like receptor 7," *Proc Natl Acad Sci U S A*, vol. 101, 2004, pp. [doi:5598-603. 10.1073/pnas.0400937101](https://doi.org/10.1073/pnas.0400937101)
- [5] A. Garcia-Sastre and C. A. Biron, "Type 1 interferons and the virus-host relationship: a lesson in detente," *Science*, vol. 312, 2006, pp. 879-82. [doi: 10.1126/science.1125676](https://doi.org/10.1126/science.1125676)
- [6] J. Pirhonen, T. Sareneva, M. Kurimoto, I. Julkunen, and S. Matikainen, "Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway," *J Immunol*, vol. 162, 1999, pp. 7322-9.
- [7] G. T. Belz, S. Bedoui, F. Kupresanin, F. R. Carbone, and W. R. Heath, "Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells," *Nat Immunol*, vol. 8, 2007, pp. 1060-6. [doi: 10.1038/ni1505](https://doi.org/10.1038/ni1505)
- [8] J. F. Fonteneau, M. Gilliet, M. Larsson, I. Dasilva, C. Munz, Y. J. Liu, and N. Bhardwaj, "Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity," *Blood*, vol. 101, 2003, pp. 3520-6. [doi: 10.1182/blood-2002-10-3063](https://doi.org/10.1182/blood-2002-10-3063)
- [9] L. D. Devanur and J. R. Kerr, "Chronic fatigue syndrome," *J Clin Virol*, vol. 37, 2006, pp. 139-50. [doi: 10.1016/j.jcv.2006.08.013](https://doi.org/10.1016/j.jcv.2006.08.013)
- [10] S. B. Harvey, M. Wadsworth, S. Wessely, and M. Hotopf, "Etiology of chronic fatigue syndrome: testing popular hypotheses using a national birth cohort study," *Psychosom Med*, vol. 70, 2008, pp. 488-95. [doi: 10.1097/PSY.0b013e31816a8dbc](https://doi.org/10.1097/PSY.0b013e31816a8dbc)

- [11] D. V. Ablashi, H. B. Eastman, C. B. Owen, M. M. Roman, J. Friedman, J. B. Zabriskie, D. L. Peterson, G. R. Pearson, and J. E. Whitman, "Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients," *J Clin Virol*, vol. 16, 2000, pp. 179-91.
- [12] S. H. Beqaj, A. M. Lerner, and J. T. Fitzgerald, "Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome," *J Clin Pathol*, vol. 61, 2008, pp. 623-6. doi: [10.1136/jcp.2007.050633](https://doi.org/10.1136/jcp.2007.050633)
- [13] D. Buchwald, M. H. Wener, T. Pearlman, and P. Kith, "Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome," *J Rheumatol*, vol. 24, 1997, pp. 372-6.
- [14] E. DeFreitas, B. Hilliard, P. R. Cheney, D. S. Bell, E. Kiggundu, D. Sankey, Z. Wroblewska, M. Palladino, J. P. Woodward, and H. Koprowski, "Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome," *Proc Natl Acad Sci U S A*, vol. 88, 1991, pp. 2922-6.
- [15] D. Gold, R. Bowden, J. Sixbey, R. Riggs, W. J. Katon, R. Ashley, R. M. Obrigewitch, and L. Corey, "Chronic fatigue. A prospective clinical and virologic study," *JAMA*, vol. 264, 1990, pp. 48-53.
- [16] B. Grinde, "Is chronic fatigue syndrome caused by a rare brain infection of a common, normally benign virus?," *Med Hypotheses*, vol. 71, 2008, pp. 270-4. doi: [10.1016/j.mehy.2008.03.014](https://doi.org/10.1016/j.mehy.2008.03.014)
- [17] J. F. Jones, "Epstein-Barr virus and the chronic fatigue syndrome: a short review," *Microbiol Sci*, vol. 5, 1988, pp. 366-9.
- [18] A. Linde, B. Andersson, S. B. Svenson, H. Ahrne, M. Carlsson, P. Forsberg, H. Hugo, A. Karstorp, R. Lenkei, A. Lindwall, and *et al.*, "Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome," *J Infect Dis*, vol. 165, 1992, pp. 994-1000.
- [19] E. W. Brenu, D. R. Staines, O. K. Baskurt, K. J. Ashton, S. B. Ramos, R. M. Christy, and S. M. Marshall-Gradisnik, "Immune and hemorheological changes in chronic fatigue syndrome," *J Transl Med*, vol. 8, 2010, p. 1. doi: [10.1186/1479-5876-8-1](https://doi.org/10.1186/1479-5876-8-1)
- [20] N. G. Klimas and A. O. Koneru, "Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions," *Curr Rheumatol Rep*, vol. 9, 2007, pp. 482-7.
- [21] M. Maes, I. Mihaylova, and J. C. Leunis, "Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins," *Neuro Endocrinol Lett*, vol. 27, 2006, pp. 615-21.
- [22] D. Racciatti, M. Dalessandro, L. Delle Donne, K. Falasca, P. Zingariello, R. Paganelli, E. Pizzigallo, and J. Vecchiet, "Study of immune alterations in patients with chronic fatigue syndrome with different etiologies," *Int J Immunopathol Pharmacol*, vol. 17, 2004, pp. 57-62.
- [23] F. Friedberg, L. Dechene, M. J. McKenzie, 2nd, and R. Fontanetta, "Symptom patterns in long-duration chronic fatigue syndrome," *J Psychosom Res*, vol. 48, 2000, pp. 59-68. doi: [10.1016/S0022-3999\(99\)00077-X](https://doi.org/10.1016/S0022-3999(99)00077-X)
- [24] "Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome," *CMAJ*, vol. 149, 1993, pp. 314-9.
- [25] S. Appel, J. Chapman, and Y. Shoenfeld, "Infection and vaccination in chronic fatigue syndrome: myth or reality?," *Autoimmunity*, vol. 40, 2007, pp. 48-53. doi: [10.1080/08916930701197273](https://doi.org/10.1080/08916930701197273)
- [26] G. Delage, I. Salit, R. Pennie, M. Alary, B. Duval, and B. Ward, "[The possible relation between hepatitis B vaccination and chronic fatigue syndrome]," *Union Med Can*, vol. 122, 1993, pp. 278-9.
- [27] O. D. Ortega-Hernandez and Y. Shoenfeld, "Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence?," *Ann N Y Acad Sci*, vol. 1173, 2009, pp. 600-9. doi: [10.1111/j.1749-6632.2009.04799.x](https://doi.org/10.1111/j.1749-6632.2009.04799.x)
- [28] K. M. Sleight, D. G. Danforth, R. T. Hall, J. A. Fleming, and H. G. Stiver, "Double-blind, randomized study of the effects of influenza vaccination on the specific antibody response and clinical course of patients with chronic fatigue syndrome," *Can J Infect Dis*, vol. 11, 2000, pp. 267-73.
- [29] K. M. Sleight, F. H. Marra, and H. G. Stiver, "Influenza vaccination: is it appropriate in chronic fatigue syndrome?," *Am J Respir Med*, vol. 1, 2002, pp. 3-9.
- [30] E. W. Brenu, M. L. van Driel, D. R. Staines, K. J. Ashton, S. B. Ramos, J. Keane, N. G. Klimas, and S. M. Marshall-Gradisnik, "Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis," *Journal of translational medicine*, vol. 9, 2011, p. 81. doi: [10.1186/1479-5876-9-81](https://doi.org/10.1186/1479-5876-9-81)
- [31] K. Fukuda, S. E. Straus, I. Hickie, M. C. Sharpe, J. G. Dobbins, and A. Komaroff, "The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group," *Ann Intern Med*, vol. 121, 1994, pp. 953-9. doi:
- [32] (2012). *The Australian Immunisation Handbook 9th Edition 2008 (9th ed.)*. Available: <http://www.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-influenza>
- [33] J. P. Aubry, A. Blaecke, S. Lecoanet-Henchoz, P. Jeannin, N. Herbault, G. Caron, V. Moine, and J. Y. Bonnefoy, "Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity," *Cytometry*, vol. 37, 1991, pp. 197-204. doi: [10.1002/\(SICI\)1097-0320\(19991101](https://doi.org/10.1002/(SICI)1097-0320(19991101)
- [34] L. Dickson and K. Finlayson, "VPAC and PAC receptors: From ligands to function," *Pharmacol Ther*, vol. 121, 2009, pp. 294-316. doi: [10.1016/j.pharmthera.2008.11.006](https://doi.org/10.1016/j.pharmthera.2008.11.006)
- [35] P. C. Doherty and A. Kelso, "Toward a broadly protective influenza vaccine," *The Journal of clinical investigation*, vol. 118, 2008, pp. 3273-5. doi: [10.1172/JCI37232](https://doi.org/10.1172/JCI37232)
- [36] Y. Ghendon, S. Markushin, Y. Vasiliev, I. Akopova, I.

- Koptiaeva, G. Krivtsov, O. Borisova, N. Ahmatova, E. Kurbatova, S. Mazurina, and V. Gervazieva, "Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally," *Journal of medical virology*, vol. 81, 2009, pp. 494-506. doi: [10.1002/jmv.21415](https://doi.org/10.1002/jmv.21415)
- [37] S. M. Hsieh and S. C. Chang, "Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian influenza (H5N1) virus," *Journal of immunology*, vol. 176, 2006, pp. 4530-3.
- [38] X. S. He, T. H. Holmes, K. Mahmood, G. W. Kemble, C. L. Dekker, A. M. Arvin, and H. B. Greenberg, "Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines," *The J Infect Dis.*, vol. 197, 2008, pp. 803-11. doi: [10.1086/528804](https://doi.org/10.1086/528804)
- [39] J. Mysliwska, P. Trzonkowski, E. Szmit, L. B. Brydak, M. Machala, and A. Mysliwski, "Immunomodulating effect of influenza vaccination in the elderly differing in health status," *Exp Gerontol*, vol. 39, 2004, pp. 1447-58. doi: [10.1016/j.exger.2004.08.005](https://doi.org/10.1016/j.exger.2004.08.005)
- [40] J. E. McElhaney, S. Gravenstein, C. M. Upshaw, J. W. Hooton, P. Krause, P. Drinka, and R. C. Bleackley, "Granzyme B: a marker of risk for influenza in institutionalized older adults," *Vaccine*, vol. 19, 2001, pp. 3744-51. doi: [10.1016/S0264-410X\(01\)00087-1](https://doi.org/10.1016/S0264-410X(01)00087-1)
- [41] J. M. Schapiro, Y. Segev, L. Rannon, M. Alkan, and B. Rager-Zisman, "Natural killer (NK) cell response after vaccination of volunteers with killed influenza vaccine," *J Med Virology*, vol. 30, 1990, pp. 196-200. doi: [10.1002/jmv.1890300310](https://doi.org/10.1002/jmv.1890300310)
- [42] R. Clark, N. B. Anderson, V. R. Clark, and D. R. Williams, "Racism as a stressor for African Americans. A biopsychosocial model," *The American psychologist*, vol. 54, 1999, pp. 805-16. doi: [10.1037/0003-066X.54.10.805](https://doi.org/10.1037/0003-066X.54.10.805)
- [43] V. Demicheli, D. Rivetti, J. J. Deeks, and T. O. Jefferson, "Vaccines for preventing influenza in healthy adults," *Cochrane database of systematic reviews*, p. CD001269, 2000.
- [44] I. Rosenkrands, C. Vingsbo-Lundberg, T. J. Bundgaard, T. Lindstrom, V. Enouf, S. van der Werf, P. Andersen, and E. M. Agger, "Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes," *Vaccine*, vol. 29, 2011, pp. 6283-91. doi: [10.1016/j.vaccine.2011.06.040](https://doi.org/10.1016/j.vaccine.2011.06.040)
- [45] J. E. McElhaney, S. Gravenstein, P. Krause, J. W. Hooton, C. M. Upshaw, and P. Drinka, "Assessment of markers of the cell-mediated immune response after influenza virus infection in frail older adults," *Clin Diagn Lab Immunol*, vol. 5, 1998, pp. 840-4.
- [46] J. E. McElhaney, S. Gravenstein, C. M. Upshaw, J. W. Hooton, P. Krause, and P. Drinka, "Immune response to influenza vaccination in institutionalized elderly: effect on different T-cell subsets," *Vaccine*, vol. 16, 1998, pp. 403-9. doi: [10.1016/S0264-410X\(97\)80918-8](https://doi.org/10.1016/S0264-410X(97)80918-8)